Events

• R&D Center NovaMedica Innotech ready to double the capacity of pharmaceutical research and manufacturing projects

  12 May 2022

  

  R&D Center NovaMedica Innotech has celebrated its 5th anniversary. The Center was created during implementation of the R&D strategy of its parent company NovaMedica (RUSNANO’s portfolio asset), which is 10 years old this year. Innotech does projects under NovaMedica’s own R&D program and offers to its partners services in development of new drugs and in contract manufacturing of solid dosage forms.

• NovaMedica Launches Own Innovative Drug for the Treatment of Alzheimer’s Disease

  19 April 2022

  

  Russian pharmaceutical company NovaMedica (investment project of RUSNANO) has developed and registered an innovative combination of Donepezil and Memantine molecules, which are the basic therapy for dementia associated with Alzheimer's disease. The drug is registered under the name MIOREOL®. This is the first such combination in the Russian market and in the markets of the EAEU and Europe.

• Timofey Petrov appointed Director General of Innotech

  25 October 2021

  

  Russian pharmaceutical company NovaMedica announces appointment of Timofey PETROV as the head of the R&D Center NovaMedica Innotech (subsidiary of NovaMedica).

• Innotech renews manufacturing license

  21 September 2021

  

  R&D Center NovaMedica Innotech has successfully passed the audit of the Ministry of Industry and Trade and received a renewed and extended manufacturing license for production of pharmaceutical drugs, which creates new contracting opportunities and, in addition to the already existing services, allows carrying out primary and secondary packaging of biological products.

• R&D Center NovaMedica Innotech joined Avifavir production efforts in Russia

  04 March 2021

  

  R&D Center NovaMedica Innotech (subsidiary of the pharmaceutical company NovaMedica, investment project of RUSNANO) announced release of the first commercial batch of the anti-COVID drug Avifavir® under the partnership with Kromis LLC, joint venture of the Russian Direct Investment Fund (RDIF) and the company ChemRar. NovaMedica Innotech will manufacture 100,000 units of Avifavir per month.

• "So, what is a pill made of?"

  03 March 2021

  

  We have already made a tradition of guided tours to the R&D Center NovaMedica Innotech for our most curious and precious visitors – children who come to see what their mothers and fathers do at work.

• PharmNews: NovaMedica Innotech debuts on CPhI

  09 October 2018

  

  The international exhibition CPhI has started in Madrid. And today NovaMedica Innotech is in our focus as the company that has made a bright debut at the exhibition. This Technological Center has launched in April 2017 and Moscow Mayor Sergei Sobyanin attended the opening ceremony.

• How Can the Russian R&D Industry Help the Global One?

  03 October 2018 CIS GMP news Magazine, Autumn 2018

  

  The current model of the pharmaceutical business in the context of R&D in Russia reflects the world trends. One of the striking examples is R&D Center of NovaMedica Innotech. It belongs to the group of CDMO (contract development and manufacturing organizations), whose task is to provide services following the 'one contact’ principle: pharmaceutical development, technology development, technology transfer, and manufacturing of small batches of products - both for clinical trials and for manufacturing of finished products batches (based on the GMP license).

• Penetrating the European Market

  02 October 2018 CIS GMP news Magazine, Autumn 2018

  

  NovaMedica Innotech is a first-timer at Cphl WorldWide. This is the first opportunity for the company to introduce its products to the European market. NovaMedica Innotech Technology Centre opened its doors in April 2017 in Moscow. It possesses a unique range of innovative Technology platforms for the development and pilot productions of advanced, completive and effective pharmaceuticals.

• NovaMedica registered a unique for Russia and rare for the world drug for treatment of proctologic disease

  07 June 2018

  

  The Russian pharmaceutical company NovaMedica (RUSNANO's portfolio company) has registered a unique drug Fissario® for proctologic diseases treatment, based on a new mechanism of action not used in products currently on the market. This is the first drug developed within own R&D program of NovaMedica. It is planned that it will be available to patients already in 2019.